Loading...
XNAS
MGX
Market cap81mUSD
Jul 11, Last price  
2.18USD
1D
-1.36%
1Q
47.30%
IPO
-80.66%
Name

Metagenomi Inc

Chart & Performance

D1W1MN
P/E
P/S
1.56
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
52m
+16.84%
243,00017,200,00044,756,00052,295,000
Net income
-78m
L+14.36%
-21,442,000-43,593,000-68,255,000-78,058,000
CFO
-109m
L+19.32%
24,257,00029,724,000-91,409,000-109,073,000

Profile

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
IPO date
Feb 09, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2024‑122023‑122022‑122021‑12
Income
Revenues
52,295
16.84%
44,756
160.21%
17,200
6,978.19%
Cost of revenue
141,196
217,651
63,573
Unusual Expense (Income)
NOPBT
(88,901)
(172,895)
(46,373)
NOPBT Margin
Operating Taxes
(5,513)
8,027
2,569
Tax Rate
NOPAT
(83,388)
(180,922)
(48,942)
Net income
(78,058)
14.36%
(68,255)
56.57%
(43,593)
103.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
84,013
1,012
239,594
BB yield
Debt
Debt current
5,592
3,639
1,515
Long-term debt
85,964
93,031
35,627
Deferred revenue
10,237
30,926
76,185
Other long-term liabilities
2,010
5,079
1,033
Net debt
(160,198)
(185,188)
(332,795)
Cash flow
Cash from operating activities
(109,073)
(91,409)
29,724
CAPEX
(3,114)
(9,814)
(13,977)
Cash from investing activities
(88,157)
45,734
(122,200)
Cash from financing activities
84,013
1,012
239,594
FCF
(75,892)
(212,817)
(60,060)
Balance
Cash
248,307
271,182
362,131
Long term investments
3,447
10,676
7,806
Excess cash
249,139
279,620
369,077
Stockholders' equity
(222,289)
205,743
271,675
Invested Capital
515,171
93,877
(251,850)
ROIC
229.05%
54.90%
ROCE
EV
Common stock shares outstanding
37,528
29,964
Price
3.61
 
Market cap
EV
EBITDA
(83,494)
(168,688)
(44,640)
EV/EBITDA
Interest
98
Interest/NOPBT